Skip to contentpdufa.bio

LISRAYA (brepocitinib tosylate): FDA NDA 220106

Page updated ·next FDA decision on the calendar ·Data as of Nov 19, 2026 12:24 AM ET

NDA 220106 is the FDA application for LISRAYA (brepocitinib tosylate). The FDA's Orange Book lists the applicant of record as PRIOVANT THERAPEUTICS INC and the first approval on it as Aug 27, 2026. Code name used in development: PF-06700841. Owner today: Roivant Sciences Ltd. (Nasdaq: ROIV).

Page updated Nov 19, 2026. FDA records: Drugs@FDA NDA 220106 · Orange Book NDA 220106

Names for this drug

Brand name (FDA)LISRAYA
Orange Book trade name: LISRAYA
Active ingredient (FDA)BREPOCITINIB TOSYLATE
Code namePF-06700841
Source: Pfizer clinical study report synopsis, May 20, 2021
“Investigational Product: Brepocitinib (PF-06700841)”

Who holds the application

FDA applicant of recordPRIOVANT THERAPEUTICS INC
FDA Orange Book data files as of Nov 13, 2026
Owner todayRoivant Sciences Ltd. (ROIV)
Source: Roivant Sciences press release (8-K exhibit 99.1), Aug 27, 2026
“Roivant (Nasdaq: ROIV) today announced that the U.S. Food and Drug Administration (FDA) has approved”
Earlier / partnerPfizer: holds a minority stake in the FDA applicant
Source: Roivant Sciences investor presentation (8-K exhibit 99.1), Aug 28, 2026
“ROIV owns 71%1 of Priovant, with Pfizer owning 24%.” … “As of June 30, 2026. 65% on a fully diluted basis.”

Products on NDA 220106 (FDA Orange Book)

No.Trade nameForm; routeStrengthApproved
001LISRAYATABLET;ORALEQ 30MG BASEAug 27, 2026

FDA decisions we track for this drug

Brepocitinib (VALOR)PFE · DecidedBrepocitinib - (VALOR)ROIV · Decided

Drug page: /drug/brepocitinib

Orange Book data: FDA Orange Book data files, as of Nov 13, 2026. Approval dates are the FDA's dates for each product; a later supplement (a new use) does not change them.